

**NOVELTY** **ENGINE** **GENERIC** **S**

INNOVATIVE DRUG DELIVERY FOR ACUTE CONDITIONS

NOVELTY ENGENERICS products are Generic Drugs in an Effervescent Formulation for Quick absorption and rapid action

Effervescent formulations are especially useful in Acute Conditions like Pain, Allergy and Sexual Health, WHERE SPEED OF ACTION IS MOST IMPORTANT

With our innovative Swiss technology, we develop formulations that provide Innovative Drug Delivery for Acute Conditions

Effective mucolytic, antioxidant and anti-inflammatory therapy for acute and chronic respiratory conditions with abundant mucous secretions

## NOVELTY ACETYL CYSTEINE effervescent



### INDICATIONS

#### 200 mg

Mucolytic, non-infective secretions in cystic fibrosis & respiratory conditions

#### 600 mg

Pulmonary conditions, reduction of the bronchial secretion, productive coughing in asthma, bronchitis, emphysema, mucoviscidose and bronchiectasis

#### 900 mg

Respiratory disease characterized by dense & viscous hypersecretion, acute bronchitis, chronic bronchitis and hisreacutisation, pulmonary emphysema, mucoviscidosis & bronchiectasis.

#### 1200 mg

Disposal and reduction of high viscous sputum to facilitate expectoration in bronchopulmonary diseases. Prevention of liver failure caused by paracetamol overage

- › Reduces the viscosity of expectorated phlegm, reduces cough severity and improves ease of expectoration
- › Reduces the risk of re-hospitalization for COPD exacerbation by approximately 30%
- › Reduces lung function decline and provides relief in difficulties associated with respiration
- › Improves the clinical outcomes and symptoms in COPD patients
- › Has a good safety profile for chronic use

### KEY FEATURES

- **NOVELTY ACETYL CYSTEINE** contains N-acetylcysteine (NAC) which is a cysteine derivative with a reactive free thiol (sulfhydryl) group, possessing both mucolytic and antioxidant properties<sup>1,2</sup>
- **NOVELTY ACETYL CYSTEINE** decreases the viscosity of secretions by splitting of disulphide linkages in the mucoproteins<sup>2</sup>
- **NOVELTY ACETYL CYSTEINE** serves as a precursor to glutathione<sup>1,3</sup>
- **NOVELTY ACETYL CYSTEINE** neutralizes oxidants exhibiting pathogenesis of inflammatory respiratory airways disease<sup>1</sup>
- **NOVELTY ACETYL CYSTEINE** absorption after oral administration is prompt and complete<sup>4,5</sup>



Composition	Per Tablet
N-acetylcysteine	200 mg
N-acetylcysteine	600 mg
N-acetylcysteine	900 mg
N-acetylcysteine	1200 mg

<b>DOSAGE</b>	1 Tablet daily	<b>FLAVOUR</b>	Orange
<b>SKU</b>	200 mg: 10 Effervescent Tablets Per Tube, Box of 2 Tubes 600 mg: 10 Effervescent Tablets Per Tube, Box of 1 Tube 900 mg: 4 Effervescent Tablets Per Strip, Box of 8 Strips 1200 mg: 20 Effervescent Tablets Per Tube, Box of 1 Tube		

### REFERENCES:

1. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. *Eur Respir J.* 2004;23(4):629-636.
2. Sheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. *Am Rev Respir Dis* 1964 Nov;90:721-729.
3. Dickinson DA, Moellering DR, Iles KE, et al. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. *Biol Chem.* 2003;384(4):527-537.
4. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. *Respir Med* 1994;88(7):531-535.
5. British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. *Thorax* 1985;40(11):832-835.

Effective mucolytic, antioxidant and anti-inflammatory therapy for acute and chronic respiratory conditions with abundant mucous secretions

## NOVELTY ACETYL CYSTEINE granules




- › Reduces the viscosity of expectorated phlegm, reduces cough severity and improves ease of expectoration
- › Reduces the risk of re-hospitalization for COPD exacerbation by approximately 30%
- › Reduces lung function decline and provides relief in difficulties associated with respiration
- › Improves the clinical outcomes and symptoms in COPD patients
- › Has a good safety profile for chronic use

### KEY FEATURES

- **NOVELTY ACETYL CYSTEINE** contains N-acetylcysteine (NAC) which is a cysteine derivative with a reactive free thiol (sulfhydryl) group, possessing both mucolytic and antioxidant properties<sup>1,2</sup>
- **NOVELTY ACETYL CYSTEINE** decreases the viscosity of secretions by splitting of disulphide linkages in the mucoproteins<sup>2</sup>
- **NOVELTY ACETYL CYSTEINE** serves as a precursor to glutathione<sup>1,3</sup>
- **NOVELTY ACETYL CYSTEINE** neutralizes oxidants exhibiting pathogenesis of inflammatory respiratory airways disease<sup>1</sup>
- **NOVELTY ACETYL CYSTEINE** absorption after oral administration is prompt and complete<sup>4,5</sup>

### INDICATIONS

- Pulmonary conditions, reduction of the bronchial secretion.
- Productive coughing in asthma, bronchitis, emphysema, mucoviscidose and bronchiectasis.



Composition	Per Sachet
N-acetylcysteine	600 mg

<b>DOSAGE</b>	1 Sachet daily	<b>SKU</b>	Granules Sachet, Box of 30 Sachets	<b>FLAVOUR</b>	Orange
---------------	----------------	------------	------------------------------------	----------------	--------

#### REFERENCES:

1. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. *Eur Respir J.* 2004;23(4):629-636.
2. Sheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. *Am Rev Respir Dis* 1964 Nov;90:721-729.
3. Dickinson DA, Moellering DR, Iles KE, et al. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. *Biol Chem.* 2003;384(4):527-537.
4. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. *Respir Med* 1994;88(7):531-535.
5. British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. *Thorax* 1985;40(11):832-835.

Effective in preventing bone loss and changes in biochemical markers of bone turnover

## NOVELTY CALCIO D3 effervescent



- › Helps in the development, maintenance and strengthening of healthy bones
- › Helps reduce the risk of bone fractures and osteoporosis
- › Helps prevent bone loss and maintain bone density
- › Helps prevent muscle cramps
- › Helps enhance calcium absorption with Vitamin D3
- › Helps bone mineralization and provides superior skeletal support

### KEY FEATURES

- **NOVELTY CALCIO D3** contains Calcium & Vitamin D3 which slows down the progression of bone loss<sup>1</sup>
- **NOVELTY CALCIO D3** contains Vitamin D3 which facilitates the calcium absorption<sup>1</sup>
- **NOVELTY CALCIO D3** has anti-inflammatory and free radical-scavenging properties. It also increases the levels of the bone-formation marker osteocalcin<sup>2</sup>
- **NOVELTY CALCIO D3** supplementation prevents bone loss in elderly women primarily by slowing bone resorption and suppressing bone turnover<sup>3</sup>
- **NOVELTY CALCIO D3** has a protective effect of Vitamin D on fractures<sup>4-5</sup>

### INDICATIONS

- Prevention and treatment of Vitamin D3 & Calcium deficiency
- Prevention and treatment of diseases such as osteoporosis and osteomalacia caused due to deficiency of Vitamin D3 and Calcium



Composition	Per Tablet
Calcium	600 mg
Vitamin D3	400 I.U.

<b>DOSAGE</b>	1 Tablet daily	<b>SKU</b>	15 Effervescent Tablets per Tube, Box of 2 Tubes	<b>FLAVOUR</b>	Orange
---------------	----------------	------------	--	----------------	--------

### REFERENCES:

1. Erik Roj Larsen, Leif Mosekilde and Anders Foldspang. Vitamin D and Calcium Supplementation Prevents Osteoporotic Fractures in Elderly Community Dwelling Residents: A Pragmatic Population-Based 3-Year Intervention Study, *Journal of Bone And Mineral Research* Volume 19, Number 3, 2004.
2. Lindsey M Locks, Karim P Manji, Christine M McDonald, Roland Kupka, Rodrick Kisenge, Said Aboud, Molin Wang, Wafaie W Fawzi, and Christopher P Duggan.; Effect of zinc and multivitamin supplementation on the growth of Tanzanian children aged 6–84 wk: a randomized, placebo-controlled, double-blind trial.; *Am J Clin Nutr* 2016;103:910–8.
3. A Mottaghi, S. Ebrahimof, P. Angoorani & A.-A. Saboor-Yaraghi.; Vitamin A Supplementation Reduces IL-17 and RORc Gene Expression in Atherosclerotic Patients, *Human Immunology* April 2014doi: 10.1111/sji.12190.
4. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997; 337:670–6.
5. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. *J Clin Endocrinol Metab* 1995;80:1052– 8.

Effervescent Brands	Contents
Novelty Paracetamol 500	Paracetamol 500 mg
Novelty Paracetamol 1000	Paracetamol 1000 mg
Novelty Ibuprofen 200	Ibuprofen 200 mg
Novelty Ibuprofen 400	Ibuprofen 400 mg
Novelty Dexketoprofen	Dexketoprofen 25 mg
Novelty Tramadol	Tramadol 50 mg
Novelty Tadalafil	Tadalafil 10 mg
Novelty Sildenafil	Sildenafil 50 mg
Novelty Desloratadine 2.5	Desloratadine 2.5 mg
Novelty Desloratadine 10	Desloratadine 10 mg
Novelty Levocetirizine	Levocetirizine 5 mg
Novelty Iron	Ferrous Gluconate (Iron 80 mg)
Novelty Zinc 25	Zinc Sulphate (Zinc 25 mg)
Novelty Zinc 50	Zinc Sulphate (Zinc 50 mg)
Novelty Magnesium	Magnesium Oxide (Magnesium 300 mg)